PeptideLabs Logo
PeptideLabs
All profiles

Lipo-C

Non-standardised blend · Blends & catalogue terms

Not a peptide and not a uniform formula. Ingredients may vary by vendor, so claims cannot be generalised.

Not FDA/EMA approved
LibraryNo account · this device only

Also known as: Lipo-C LC120 · LC120 · Lipotropic blend · Lipo-C injection

Use at a glance

Lipo-C

Not a peptide and not a uniform formula. Ingredients may vary by vendor, so claims cannot be generalised.

Online report · not medically verified

What amount?
0.5–1 ml
How often?
1–2 times per week
What time of day?
not reliably established
In what setting?
community reports

A U figure only applies to the source's exact composition, concentration and device scale. Without all three, it cannot be transferred to another blend vial or pen.

How is it used?
Identify every ingredient and its amount first. The same blend name can refer to different products.
Does it need mixing?
Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.
View preparationCheck sources
More factsNon-standardised blend · Blends & catalogue terms
Classification
Non-standardised blend · Blends & catalogue terms
Research focus
Not a peptide and not a uniform formula. Ingredients may vary by vendor, so claims cannot be generalised.
Evidence
Anecdotal
Status
Not FDA/EMA approved

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

Community source: usually 0.5–1 ml subcutaneous or intramuscular once or twice a week, sometimes more often. This is not an mg dose because ingredients and concentrations vary.

Profile evidence level: anecdotal.

Timing

Once or twice weekly per community claims; no validated fat-loss standard.

No individual recommendation.

Cycle/duration

No uniform cycle. Composition, diagnosis and pharmacy label determine any serious assessment.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.

All preparation informationProduct details and calculation examples from the available sources.

Usually a ready-to-use variable mixture. Purely volumetrically at U-100: 0.5 ml =50 U and 1 ml =100 U; the amount of each ingredient only follows from the exact recipe/label. No blanket blend calculation.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Non-standardised vendor name for a variable lipotropic mixture

Lipo-C is classified as “Non-standardised vendor name for a variable lipotropic mixture”. Not a peptide and not a uniform formula. Ingredients may vary by vendor, so claims cannot be generalised. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Lipotropic blend marketing

This concerns blend products marketed as fat-burning, whose actual composition and effect vary greatly by vendor, similar to a generic marketing term without a fixed formula. Individual ingredients are usually studied, not the blend as a whole.

02

Fatty acid transport

This studies how substances support the transport of fatty acids into and out of cells, similar to a delivery service bringing fat to the mitochondria where it is burned. Fat metabolism markers are measured in lab and animal models.

03

Ambiguous catalog naming

This concerns a vendor name that does not correspond to a single, scientifically defined substance, similar to a nickname that could refer to different things. Researchers and analysts examine what actual composition lies behind the name.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

Vendor marketing claims

Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.

Catalog name confusion

Users try to clarify what actual substance lies behind unclear vendor names or code labels, often by comparing labels and vendor claims. Such forum guesses are not a reliable identification of a substance.

Adverse effects and safety risks

  • Blends combine not only possible effects but also uncertainty, interactions, dosing errors and stability problems. An effect cannot be assigned reliably to one component.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • No use should be inferred without full qualitative and quantitative composition, batch testing and stability data; every comorbidity and medicine adds concern.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No validated monitoring exists for non-standardised blends. Individual lab values cannot make an unknown composition or interaction safe.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Anecdotal

Because of the lack of standardisation, efficacy claims cannot be generalised.

Clinical evidence

Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.

Lipo-C is not a peptide and not a uniform formula; ingredients can vary substantially by vendor.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile